Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are Ineligible for autologous stem cell transplant: A Germany and United Kingdom retrospective study.
Bröckelmann, P Zagadailov, E Corman, S Chirikov, V Johnson, C Macahilig, C Seal, B Dalal, M
Bröckelmann, P
Zagadailov, E
Corman, S
Chirikov, V
Johnson, C
Macahilig, C
Seal, B
Dalal, M
Citations
Altmetric:
Abstract
Brentuximab vedotin (BV) is an anti-CD30 antibody-drug conjugate licensed for the treatment of relapsed/refractory Hodgkin lymphoma (rrHL) following autologous stem cell transplant (ASCT) or at least two prior therapies when ASCT or multiagent chemotherapy is not an option. The objective of this study was to describe real-world outcomes with BV in patients with rrHL considered ASCT ineligible or who refuse ASCT.
Description
Lymphoma Research Team
Date
2017-09-26
Publisher
Collections
Keywords
Type
Article
Citation
Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are Ineligible for autologous stem cell transplant: A Germany and United Kingdom retrospective study. 2017, Eur J Haematol